New York/Frankfurt (Reuters) – The German group Merck confirmed on Monday being in advanced discussions to buy the American firm Springworks Therapeutics, specialized in the treatment of rare cancers and illnesses, as Reuters had earned earlier, citing sources in Make the file.
In a statement, Merck said that the negotiations were underway and that no legally binding agreement had been signed with Springworks. There is no guarantee that these negotiations will succeed, he added.
Springworks refused to comment.
It is possible that an agreement is signed in the coming weeks, three informed sources told Reuters earlier, without giving details on the contours of such a potential agreement.
Springworks, whose title ended up 34% on Monday, is valued at around $ 4 billion. Earlier in the session, reacting to Reuters’s information, he had jumped 49% to settle for a higher since April 2022.
Merck, listed in Germany, lost 3.7% on Monday.
Transactions in the American health sector seem to experience a new breath at the start of 2025, while Johnson & Johnson sealed an agreement in January to acquire Intra-Cellular Therapeutics for around $ 14.6 billion.
(Sabrina Valle in New York and Patricia Weiss in Frankfurt; Jean Terzian)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
